Cargando…

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis

Biomarkers are needed for predicting the effectiveness of disease modifying antirheumatic drugs (DMARDs). Here, using functional lipid mediator profiling and deeply phenotyped patients with early rheumatoid arthritis (RA), we observe that peripheral blood specialized pro-resolving mediator (SPM) co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, Esteban A., Colas, Romain A., Souza, Patricia R., Hands, Rebecca, Lewis, Myles J., Bessant, Conrad, Pitzalis, Costantino, Dalli, Jesmond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591509/ https://www.ncbi.nlm.nih.gov/pubmed/33110080 http://dx.doi.org/10.1038/s41467-020-19176-z

Ejemplares similares

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Follicular dendritic cell differentiation is associated with distinct synovial pathotype signatures in rheumatoid arthritis
por: El Shikh, Mohey Eldin M., et al.
Publicado: (2022)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
por: Flak, Magdalena B., et al.
Publicado: (2019)

Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
por: Flak, Magdalena B., et al.
Publicado: (2022)

Protective activities of distinct omega-3 enriched oils are linked to their ability to upregulate specialized pro-resolving mediators
por: Sobrino, Agua, et al.
Publicado: (2020)

MCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis
por: Pistorius, Kimberly, et al.
Publicado: (2022)

Utility of the Specialized Pro-Resolving Mediators as Diagnostic and Prognostic Biomarkers in Disease
por: Dalli, Jesmond, et al.
Publicado: (2022)

Loss of 15-lipoxygenase disrupts T(reg) differentiation altering their pro-resolving functions
por: Marques, Raquel M., et al.
Publicado: (2021)

Pro-Resolving Mediators in Regulating and Conferring Macrophage Function
por: Dalli, Jesmond, et al.
Publicado: (2017)

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients
por: Nerviani, Alessandra, et al.
Publicado: (2020)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis
por: Micheroli, Raphael, et al.
Publicado: (2022)

Circulating and Synovial Pentraxin-3 (PTX3) Expression Levels Correlate With Rheumatoid Arthritis Severity and Tissue Infiltration Independently of Conventional Treatments Response
por: Boutet, Marie-Astrid, et al.
Publicado: (2021)

Reply to: Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples
por: Dalli, Jesmond, et al.
Publicado: (2023)

Network analysis of synovial RNA sequencing identifies gene-gene interactions predictive of response in rheumatoid arthritis
por: Sciacca, Elisabetta, et al.
Publicado: (2022)

Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology
por: Dalli, Jesmond, et al.
Publicado: (2018)

Vagus nerve controls resolution and pro-resolving mediators of inflammation
por: Mirakaj, Valbona, et al.
Publicado: (2014)

GPR101 mediates the pro-resolving actions of RvD5(n-3 DPA) in arthritis and infections
por: Flak, Magdalena B., et al.
Publicado: (2019)

Synthesis and Anti-inflammatory and Pro-resolving Activities of 22-OH-PD1, a Monohydroxylated Metabolite of Protectin D1
por: Tungen, Jørn E., et al.
Publicado: (2014)

Total Synthesis of the Lipid Mediator PD1(n-3 DPA): Configurational Assignments and Anti-inflammatory and Pro-resolving Actions
por: Aursnes, Marius, et al.
Publicado: (2014)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis
por: Walker, Mary E., et al.
Publicado: (2017)

Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure
por: Scirè, Carlo Alberto, et al.
Publicado: (2007)

Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?
por: Humby, Frances Claire, et al.
Publicado: (2017)

Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways
por: Walsh, Alice M., et al.
Publicado: (2017)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Stratified medicine in rheumatoid arthritis—the MATURA programme
por: Barton, Anne, et al.
Publicado: (2017)

Self-Limited versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA
por: Fredman, Gabrielle, et al.
Publicado: (2012)

Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli–driven acute inflammation
por: Motwani, Madhur P., et al.
Publicado: (2018)

Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis
por: Ferrari, Mathieu, et al.
Publicado: (2021)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
por: Fosshaug, Linn E., et al.
Publicado: (2019)

CORRIGENDUM: Novel n-3 Immunoresolvents: Structures and Actions
por: Dalli, Jesmond, et al.
Publicado: (2014)

Novel n-3 Immunoresolvents: Structures and Actions
por: Dalli, Jesmond, et al.
Publicado: (2013)

Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention
por: Dalli, Jesmond, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bm4p1jkhc09n73re8ft29hlkit